최소 단어 이상 선택하여야 합니다.
최대 10 단어까지만 선택 가능합니다.
다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
NTIS 바로가기다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
DataON 바로가기다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
Edison 바로가기다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
Kafe 바로가기국가/구분 | United States(US) Patent 등록 |
---|---|
국제특허분류(IPC7판) |
|
출원번호 | US-0833200 (2004-04-27) |
등록번호 | US-8236048 (2012-08-07) |
발명자 / 주소 |
|
출원인 / 주소 |
|
인용정보 | 피인용 횟수 : 1 인용 특허 : 461 |
A drug and drug delivery system may be utilized in the treatment of vascular disease. A local delivery system is coated with rapamycin or other suitable drug, agent or compound and delivered intraluminally for the treatment and prevention of neointimal hyperplasia following percutaneous transluminal
A drug and drug delivery system may be utilized in the treatment of vascular disease. A local delivery system is coated with rapamycin or other suitable drug, agent or compound and delivered intraluminally for the treatment and prevention of neointimal hyperplasia following percutaneous transluminal coronary angiography. The local delivery of the drugs or agents provides for increased effectiveness and lower systemic toxicity.
1. A drug delivery device comprising: an intraluminal medical device, the intraluminal medical device including a stent having a fenestrated structure, the stent comprising a plurality of bands and links defining a substantially tubular device with openings;a polymeric coating affixed to the bands a
1. A drug delivery device comprising: an intraluminal medical device, the intraluminal medical device including a stent having a fenestrated structure, the stent comprising a plurality of bands and links defining a substantially tubular device with openings;a polymeric coating affixed to the bands and links of the fenestrated structure, the polymeric coating including first and second layers; anda therapeutic dosage of rapamycin incorporated into the polymeric coating for treatment of intimal hyperplasia, constrictive vascular remodeling, and inflammation caused by injury, the rapamycin being incorporated into the first layer of the polymeric coating, the first layer comprising a solution of ethylene-co-vinylacetate and polybutylmethacrylate, and the second layer, comprising polybutylmethacrylate and acting as a diffusion layer, the first layer having a thickness in the range from about eight microns to about twelve microns and the second layer having a thickness in the range from about one micron to about two microns, the rapamycin being configured for release over a period of about seven to thirty days and having a dosage in the range from about 35 to 430 micrograms per 15 to 18 mm length stents thereby producing a peak 50 to 55 percent reduction in neointimal hyperplasia.
Copyright KISTI. All Rights Reserved.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.